Lonza shows improvement at low end of forecast

- Last updated on GMT

Lonza, the maker of L-carnitine and B vitamins, said today that
profits for 2004 climbed by more than half, coming in at the low
end of analysts' forecasts.

The Swiss speciality chemicals group reported operating profits of SF212 million (€136.9m) and net income of SF138 million, a 52 per cent rise on the prior year.

The company blamed weak niacin prices, as well as the US dollar exchange rate and the postponement of biopharmaceutical deliveries until this year, on its failure to match earnings targets set at the beginning of the year.

In its organic and fine chemicals unit, the market is expected to remain competitive for a number of product lines, but the group said it will focus on niche markets in nutrition and cosmetics to support long-term profitability.

"The board of directors expects sales growth and a solid improvement in earnings in 2005 in line with our short-term, two-year operating income targets of between SF300 million and SF400 million,"​ Lonza said in a statement.

The company ruled out a restructuring of operations, something that had been widely expected in the market.

Analyst Bernd Pomrehn at Bank Sarasin told an agency report that "people were hoping they would make a move to sell their polymer intermediates but there is no sign of that"​.

Related topics: Suppliers, Vitamins & premixes

Related news

Show more

Related products

show more


12 Reasons MenaQ7® is the Superior Vitamin K2

NattoPharma USA, Inc. | 11-Sep-2017 | Data Sheet

Vitamin K2 as MK-7 supplements are truly changing the face of global health, benefiting old and young alike. We know this because NattoPharma has single-handedly...


Strategic Nutrition for Heart Health-Part II

Fortitech® Premixes by DSM | 21-Jun-2017 | Technical / White Paper

Consumers are increasingly shopping for heart healthy products. Identify nutrients that can help differentiate your products and learn how custom nutrient...

Related suppliers

Follow us


View more